Who
John David Finley
CEO CFO
Company insider
Files Form 4 as: CEO CFO, Palisade Bio.
In numbers
- Trades disclosed
- 123
- Buys
- 11
- Sells
- 2
- Bought
- $102K
- Sold
- $621K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 27 Apr 2021
- Last trade
- 6 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 7 Oct 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | —3,227,384 | filing |
| 6 Oct 2026filed 7 Oct 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code F | $2.1M1,411,982 at $1.49 | filing |
| 6 Oct 2026filed 7 Oct 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —3,059,800 at $0.00 | filing |
| 6 Oct 2026filed 7 Oct 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —167,584 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code G | —88,400 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code G | —88,400 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code G | —88,400 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code G | —88,400 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Sold | $303K146,798 at $2.07 | filing |
| 7 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | $93133 at $0.70 | filing |
| 7 Jul 2026filed 8 Jul 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —133 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —133 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Sold | $304K146,798 at $2.07 | filing |
| 7 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | $93133 at $0.70 | filing |
| 6 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | —335,167 | filing |
| 6 Jul 2026filed 8 Jul 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —335,167 at $0.00 | filing |
| 6 Jul 2026filed 8 Jul 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —335,167 at $0.00 | filing |
| 6 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | —335,167 | filing |
| 12 Feb 2026filed 13 Feb 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Sold | $6,8183,896 at $1.75 | filing |
| 12 Feb 2026filed 13 Feb 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Sold | $6,8183,896 at $1.75 | filing |
News
Analyzing Indivior (NASDAQ:INDV) and Palisade Bio (NASDAQ:PALI)PALI · dailypolitical.com · 24 Oct 2026Critical Survey: Nexentis Technologies (NASDAQ:NXTS) versus Palisade Bio (NASDAQ:PALI)PALI · themarketsdaily.com · 24 Oct 2026Palisade Bio Rises 9% As PALI-2108 Shows Early Activity In Crohn's DiseasePALI · rttnews.com · 20 Oct 2026
0 headlines in the last 90 days name John David Finley; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.